93 related articles for article (PubMed ID: 27941874)
1. HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer.
Bogoevska V; Wolters-Eisfeld G; Hofmann BT; El Gammal AT; Mercanoglu B; Gebauer F; Vashist YK; Bogoevski D; Perez D; Gagliani N; Izbicki JR; Bockhorn M; Güngör C
Oncogene; 2017 Apr; 36(17):2394-2404. PubMed ID: 27941874
[TBL] [Abstract][Full Text] [Related]
2. Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells.
Yamashita N; Saito N; Zhao S; Terai K; Hiruta N; Park Y; Bujo H; Nemoto K; Kanno Y
Exp Cell Res; 2018 May; 366(1):34-40. PubMed ID: 29501698
[TBL] [Abstract][Full Text] [Related]
3. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2.
Jiang K; Yang Z; Cheng L; Wang S; Ning K; Zhou L; Lin J; Zhong H; Wang L; Li Y; Huang J; Zhang H; Ye Q
J Biol Chem; 2013 Aug; 288(34):24590-9. PubMed ID: 23861392
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.
De Boeck A; Pauwels P; Hensen K; Rummens JL; Westbroek W; Hendrix A; Maynard D; Denys H; Lambein K; Braems G; Gespach C; Bracke M; De Wever O
Gut; 2013 Apr; 62(4):550-60. PubMed ID: 22535374
[TBL] [Abstract][Full Text] [Related]
5. Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration.
Meira M; Masson R; Stagljar I; Lienhard S; Maurer F; Boulay A; Hynes NE
J Cell Sci; 2009 Mar; 122(Pt 6):787-97. PubMed ID: 19223396
[TBL] [Abstract][Full Text] [Related]
6. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
7. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.
Lv Y; Sui F; Ma J; Ren X; Yang Q; Zhang Y; Guan H; Shi B; Hou P; Ji M
Oncotarget; 2016 Sep; 7(36):57978-57990. PubMed ID: 27517321
[TBL] [Abstract][Full Text] [Related]
9. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
[TBL] [Abstract][Full Text] [Related]
10. Hexachlorobenzene modulates the crosstalk between the aryl hydrocarbon receptor and transforming growth factor-β1 signaling, enhancing human breast cancer cell migration and invasion.
Miret N; Pontillo C; Ventura C; Carozzo A; Chiappini F; Kleiman de Pisarev D; Fernández N; Cocca C; Randi A
Toxicology; 2016 Jul; 366-367():20-31. PubMed ID: 27519288
[TBL] [Abstract][Full Text] [Related]
11. HER2 overexpression-mediated inflammatory signaling enhances mammosphere formation through up-regulation of aryl hydrocarbon receptor transcription.
Zhao S; Ohara S; Kanno Y; Midorikawa Y; Nakayama M; Makimura M; Park Y; Inouye Y
Cancer Lett; 2013 Mar; 330(1):41-8. PubMed ID: 23196063
[TBL] [Abstract][Full Text] [Related]
12. Memo interacts with c-Src to control Estrogen Receptor alpha sub-cellular localization.
Frei A; MacDonald G; Lund I; Gustafsson JÅ; Hynes NE; Nalvarte I
Oncotarget; 2016 Aug; 7(35):56170-56182. PubMed ID: 27472465
[TBL] [Abstract][Full Text] [Related]
13. Memo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active site.
Qiu C; Lienhard S; Hynes NE; Badache A; Leahy DJ
J Biol Chem; 2008 Feb; 283(5):2734-40. PubMed ID: 18045866
[TBL] [Abstract][Full Text] [Related]
14. Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells.
Zaoui K; Honoré S; Isnardon D; Braguer D; Badache A
J Cell Biol; 2008 Nov; 183(3):401-8. PubMed ID: 18955552
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
16. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
17. Aryl hydrocarbon receptor and aryl hydrocarbon nuclear translocator expression in human and rat placentas and transcription activity in human trophoblast cultures.
Stejskalova L; Vecerova L; Peréz LM; Vrzal R; Dvorak Z; Nachtigal P; Pavek P
Toxicol Sci; 2011 Sep; 123(1):26-36. PubMed ID: 21666223
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
19. Memo is a copper-dependent redox protein with an essential role in migration and metastasis.
MacDonald G; Nalvarte I; Smirnova T; Vecchi M; Aceto N; Dolemeyer A; Frei A; Lienhard S; Wyckoff J; Hess D; Seebacher J; Keusch JJ; Gut H; Salaun D; Mazzarol G; Disalvatore D; Bentires-Alj M; Di Fiore PP; Badache A; Hynes NE
Sci Signal; 2014 Jun; 7(329):ra56. PubMed ID: 24917593
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
